Visiomed Group SA
Klea Holding SA, together with its subsidiaries, provides healthcare technology and services in France and internationally. It offers BewellConnect, an eco-system of health solutions, including enriched and assisted teleconsultation, remote home monitoring, hospital monitoring, tele-expertise, tele-assistance, and tele-regulations; and Smart Salem, a medical fitness screening device. The company … Read more
Visiomed Group SA (VMDGF) - Net Assets
Latest net assets as of June 2024: $26.77 Million USD
Based on the latest financial reports, Visiomed Group SA (VMDGF) has net assets worth $26.77 Million USD as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($36.17 Million) and total liabilities ($9.40 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $26.77 Million |
| % of Total Assets | 74.02% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 35.24 |
Visiomed Group SA - Net Assets Trend (2019–2023)
This chart illustrates how Visiomed Group SA's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Visiomed Group SA (2019–2023)
The table below shows the annual net assets of Visiomed Group SA from 2019 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $24.75 Million | +1.97% |
| 2022-12-31 | $24.27 Million | +72.45% |
| 2021-12-31 | $14.07 Million | +419.09% |
| 2020-12-31 | $-4.41 Million | +13.75% |
| 2019-12-31 | $-5.11 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Visiomed Group SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2681400000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $902.00K | 3.74% |
| Other Components | $23.20 Million | 96.26% |
| Total Equity | $24.10 Million | 100.00% |
Visiomed Group SA Competitors by Market Cap
The table below lists competitors of Visiomed Group SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Coya Therapeutics, Inc. Common Stock
NASDAQ:COYA
|
$80.41 Million |
|
Unitika Ltd
PINK:UNIKF
|
$80.41 Million |
|
Trabzonspor Sportif Yatirim ve Futbol Isletmeciligi Ticaret AS
IS:TSPOR
|
$80.42 Million |
|
ROUTE MOBILE LIMITED
NSE:ROUTE
|
$80.43 Million |
|
Bursa De Valori Bucuresti SA
RO:BVB
|
$80.39 Million |
|
Horizon Minerals Ltd
AU:HRZ
|
$80.34 Million |
|
Biomea Fusion Inc
NASDAQ:BMEA
|
$80.34 Million |
|
Oxford Bank Corporation
PINK:OXBC
|
$80.28 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Visiomed Group SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 24,272,000 to 24,102,000, a change of -170,000 (-0.7%).
- Net income of 902,000 contributed positively to equity growth.
- New share issuances of 9,000 increased equity.
- Other factors decreased equity by 1,081,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $902.00K | +3.74% |
| Share Issuances | $9.00K | +0.04% |
| Other Changes | $-1.08 Million | -4.49% |
| Total Change | $- | -0.70% |
Book Value vs Market Value Analysis
This analysis compares Visiomed Group SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.49x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-0.36 | $0.45 | x |
| 2020-12-31 | $-0.17 | $0.45 | x |
| 2021-12-31 | $0.10 | $0.45 | x |
| 2022-12-31 | $0.08 | $0.45 | x |
| 2023-12-31 | $0.08 | $0.45 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Visiomed Group SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.74%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.58%
- • Asset Turnover: 0.37x
- • Equity Multiplier: 1.52x
- Recent ROE (3.74%) is above the historical average (-9.93%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | -234.96% | 0.69x | 0.00x | $-23.54 Million |
| 2020 | 0.00% | -27.14% | 3.21x | 0.00x | $-4.71 Million |
| 2021 | -31.67% | -62.14% | 0.16x | 3.13x | $-5.86 Million |
| 2022 | -21.74% | -36.53% | 0.40x | 1.49x | $-7.70 Million |
| 2023 | 3.74% | 6.58% | 0.37x | 1.52x | $-1.51 Million |
Industry Comparison
This section compares Visiomed Group SA's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $914,015,556
- Average return on equity (ROE) among peers: -22.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Visiomed Group SA (VMDGF) | $26.77 Million | 0.00% | 0.35x | $80.39 Million |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |